Retrospective Cohort Study
Copyright ©The Author(s) 2025.
World J Transplant. Sep 18, 2025; 15(3): 100111
Published online Sep 18, 2025. doi: 10.5500/wjt.v15.i3.100111
Table 1 Baseline demographics and clinical characteristics of study cohort, n (%)
Characteristics
Total (n = 70)
Normal acid exposure (n = 52)
Increased acid exposure (n = 18)
P value
Follow up, (years), mean ± SD2.23 ± 1.872.24 ± 2.032.22 ± 1.340.97
Male sex41 (58.6)30 (57.7)11 (61.1)1.00
BMI, mean ± SD26.8 ± 4.5627.4 ± 4.4025.4 ± 4.800.11
Age at transplant, mean ± SD56.3 ± 12.556.7 ± 12.555.0 ± 13.00.62
White race67 (95.7)51 (98.1)16 (88.9)0.16
Pulmonary diagnosis
ILD40 (57.1)28 (53.8)12 (66.7)0.41
IPF22 (31.4)14 (26.9)8 (44.4)0.24
COPD15 (21.4)13 (25.0)2 (11.1)0.32
Other17 (24.3)13 (25.0)4 (22.2)1.00
Cardiac function, baseline
LVEF, mean ± SD60.9 ± 5.4860.3 ± 5.7262.7 ± 4.400.11
PaP, mean ± SD26.6 ± 9.3627.7 ± 10.323.5 ± 4.620.03
PCWP, (mm Hg), mean ± SD10.3 ± 4.9010.8 ± 5.188.82 ± 3.710.16
PVR (dynes/cm5), mean ± SD225 ± 134230 ± 145212 ± 91.90.64
Pulmonary function, baseline
FVC, mean ± SD2.00 ± 0.771.99 ± 0.672.03 ± 1.010.87
FVC, %-pred, mean ± SD0.49 ± 0.150.50 ± 0.160.46 ± 0.120.29
FEV1, mean ± SD1.36 ± 0.661.32 ± 0.591.47 ± 0.850.44
FEV1, %-pred, mean ± SD0.42 ± 0.190.43 ± 0.200.40 ± 0.180.63
FEV1/FVC, mean ± SD0.69 ± 0.230.68 ± 0.230.72 ± 0.220.62
Bilateral lung transplant36 (51.4)29 (55.8)7 (38.9)0.28
CMV mismatch18 (25.7)15 (28.8)3 (16.7)0.37
Increased risk donor11 (15.7)8 (15.4)3 (16.7)1.00
Post-transplant infection30 (42.8)23 (44.3)7 (38.9)0.79
Post-transplant PPI54 (77.1)38 (73.1)16 (88.9)0.21
≥ 20% FEV1 decline18 (25.7)11 (21.1)7 (38.9)0.21